Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million init ... Subscribe now to see this Premium News article from Alliance News ...

with a 40% probability of success, via peak penetration of 15% as an add-on therapy in the incretin-treated market. BioAge (BIOA) held an upsized initial public offering on Sept. 26, raising $198M.

Celebrating his company’s upsized initial public offering (IPO), Septerna CEO Jeffrey Finer rang the opening bell on the Nasdaq stock exchange on Friday morning in New York, in the latest sign ...

(Reuters) -Biotech firm Septerna on Thursday said it raised $288 million in its initial public offering that has been upsized twice ... MBX Biosciences, BioAge Labs and Upstream Bio are also ...

RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic ...